NeuroEPO Cuba Research: What American Patients Need to Know

What Is NeuroEPO?

NeuroEPO is a recombinant human erythropoietin (EPO) preparation developed by Cuba's Center for Genetic Engineering and Biotechnology (CIGB) specifically for neurological applications. Unlike the EPO used to treat anemia (which is given intravenously or subcutaneously), NeuroEPO is formulated for intranasal delivery, allowing it to cross the blood-brain barrier and reach the central nervous system directly.

Erythropoietin has been studied worldwide for its potential neuroprotective properties — the EPO receptor is expressed in neurons, and research suggests EPO may protect against neuronal death, reduce neuroinflammation, promote neurogenesis (the growth of new neurons), and support synaptic plasticity. These properties make EPO theoretically attractive for neurodegenerative diseases like Alzheimer's, Parkinson's, and stroke recovery.

Cuba's CIGB has been at the forefront of developing NeuroEPO specifically for neurological use, conducting clinical studies in patients with mild cognitive impairment and mild-to-moderate Alzheimer's disease, as well as other neurological conditions.

Clinical Research Status

NeuroEPO for Alzheimer's disease is in the clinical research phase. This means:

• Not FDA-approved — NeuroEPO is not approved by the FDA and is not available in the United States. It is used within research protocols at Cuban neuroscience institutions. • Cuban clinical studies — CIGB has conducted clinical studies exploring NeuroEPO's safety and potential efficacy in cognitive impairment and Alzheimer's. Results have been published in peer-reviewed journals. • Mechanism of action — NeuroEPO is hypothesized to work through multiple mechanisms: anti-apoptotic effects (preventing neuronal death), anti-inflammatory effects in the brain, promotion of neurogenesis, and improvement of cerebral oxygenation. • Intranasal delivery — The intranasal route allows NeuroEPO to bypass the blood-brain barrier, which normally prevents large molecules like EPO from entering the brain. This is a key innovation of the Cuban approach. • Not a cure — NeuroEPO is not a cure for Alzheimer's disease. It is a neuroprotective approach that aims to slow cognitive decline and support remaining function. Individual outcomes vary and no result is guaranteed.

For American patients, NeuroEPO represents a research-based approach that is available only in Cuba. It is offered as part of a comprehensive program that also includes intensive cognitive rehabilitation, pharmacological management, and caregiver education — not as a standalone treatment.

NeuroEPO vs. FDA-Approved Alzheimer's Drugs

American patients often ask how NeuroEPO compares to FDA-approved Alzheimer's treatments. The comparison is not straightforward because the approaches target different aspects of the disease:

FDA-approved anti-amyloid drugs (lecanemab/Leqembi, donanemab/Kisunla): • Target: Amyloid-beta plaques in the brain • Stage: Approved for mild cognitive impairment or mild dementia due to Alzheimer's • Administration: Intravenous infusions every 2-4 weeks • Cost: $26,000+/year (drug cost alone, plus infusion and monitoring costs) • Risks: ARIA (amyloid-related imaging abnormalities), brain swelling, micro-hemorrhages • Monitoring: Regular MRI scans required

NeuroEPO (Cuba): • Target: Neuroprotection, anti-inflammation, neurogenesis support • Stage: Studied in mild cognitive impairment and mild-to-moderate Alzheimer's • Administration: Intranasal delivery • Cost: Included in the comprehensive Cuban program (not a separate drug cost) • Risks: Generally well-tolerated in studies; intranasal delivery avoids systemic side effects • Monitoring: Part of the intensive in-clinic program

The approaches are not mutually exclusive. Some patients may benefit from anti-amyloid treatment in the U.S. and intensive rehabilitation with NeuroEPO in Cuba — though this should be discussed with both your U.S. neurologist and the Cuban medical team. Patients should never discontinue prescribed medications without consulting their physician.

What U.S. Patients Should Know Before Considering NeuroEPO

If you're an American patient or family considering NeuroEPO in Cuba, here's what you need to know:

• It's investigational — NeuroEPO is not a proven, approved treatment. It is part of a research-based program. Be cautious of any source that promises guaranteed results. • It's part of a comprehensive program — NeuroEPO is not prescribed alone. It is one component of a 4-8 week intensive program that includes daily cognitive rehabilitation, pharmacological management, and caregiver training. The intensive rehabilitation is likely the primary driver of functional improvement. • Bring your records — Submit neuropsychological testing, MRI, blood work, and medication history for medical review before traveling. The team needs to confirm cognitive stage and suitability. • Caregiver involvement is essential — The program trains caregivers to continue cognitive stimulation and daily-routine support at home. Without this, gains achieved in Havana may not be maintained. • Coordinate with your U.S. neurologist — Share your Cuban medical report with your U.S. physician for coordinated care. Do not stop any prescribed medications without their guidance. • No guarantees — Alzheimer's is a progressive disease. The Cuban program aims to slow decline and maintain function, not to cure. Individual outcomes vary significantly. • Telemedicine follow-up — After returning to the U.S., periodic remote consultations with the Cuban neurology team help track progression and adjust the home program.

SMC Salud provides honest, transparent information and does not overstate the potential of NeuroEPO or any Cuban treatment. Contact us for a medical review to determine if the program is suitable for your situation.